Klaus Christian Schollmeier

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark.

Novo Nordisk Research Center Gladsaxe ApS is based in Bagsværd, Denmark. The Danish company is a spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. The company discovered a novel target that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity. The development of the target was initiated through a collaboration with Novo Nordisk and further matured with support from the Innobooster program at the Innovation Fund Denmark and the Bioinnovation Institute (BII) during a residency in the Venture House program. Part of Novo Nordisk A/S, Novo Nordisk Research Center Gladsaxe ApS is a biotech company that was founded in 2017. The CEO of the company is Casper Tind Hansen. Novo Nordisk Research Center Gladsaxe was acquired by Novo Nordisk A/S from Embark Laboratories ApS on August 28, 2023 for $68.06 million.

Churney ApS is a company based in Copenhagen, Denmark. The Danish company was founded by Casper Tind Hansen, Christian Hansen, Noy Rotbart, Brian Brost. Noy Rotbart has been the CEO of the company since 2021.